Quanta Dialysis Technologies, a UK-based medical device maker backed by medical gases and equipment producer Air Liquide and engineering firm IMI, secured $48m in series C funding yesterday.
B-to-V Partners, Wellington Partners, Seroba Life Sciences and an unnamed Swiss family office co-led the round, which also featured undisclosed existing investors. The $48m figure represents a first tranche, but Quanta did not reveal a target close.
Spun off from IMI in 2008 as Quanta Fluid Solutions, the company has developed a compact haemodialysis system called SC+ to help kidney disease patients purify their blood.
The device relies on a lightweight, disposable cartridge and can be operated by patients at home, removing the need for regular hospital visits.
The device has been successfully trialed with the UK’s National Health Service and secured regulatory approval in the European Union. The capital will go towards a commercial launch of SC+ in the UK and will support Quanta in seeking regulatory approval in the US.
IMI joined Air Liquide’s corporate venturing division, Aliad, to participate in Quanta’s $43m series B round in 2014 together with Seventure Partners, B-to-V, Wellington Partners, Seroba Life Sciences and NBGI Ventures. The latter four had previously supplied $14.3m in series A funding for the company in 2009.
